Line 87: | Line 87: | ||
</div> | </div> | ||
<br> | <br> | ||
− | <p>The goal of this project is to construct a novel fusion protein of gold binding polypeptides (GBP)-protein G (ProG) to develop an electrochemical biosensor for rapid and simple diagnosis and monitoring heart failure.</p | + | <p>The goal of this project is to construct a novel fusion protein of gold binding polypeptides (GBP)-protein G (ProG) to develop an electrochemical biosensor for rapid and simple diagnosis and monitoring heart failure.</p> |
<p>DH5-alpha E. coli strain was transformed by a genetically modified recombinant vector coding GBP and ProG. The GBP-ProG fusion protein was derived from the strain with IPTG-induced expression and purified using the TALON metal affinity resin. The resulting GBP-ProG was directly self-immobilized onto gold surfaces via the GBP portion, followed by the oriented binding of antibodies onto the ProG domain targeting the Fc region of antibodies.</p> | <p>DH5-alpha E. coli strain was transformed by a genetically modified recombinant vector coding GBP and ProG. The GBP-ProG fusion protein was derived from the strain with IPTG-induced expression and purified using the TALON metal affinity resin. The resulting GBP-ProG was directly self-immobilized onto gold surfaces via the GBP portion, followed by the oriented binding of antibodies onto the ProG domain targeting the Fc region of antibodies.</p> | ||
</section> | </section> |
Revision as of 13:14, 30 September 2018
ABSTRACT
The goal of this project is to construct a novel fusion protein of gold binding polypeptides (GBP)-protein G (ProG) to develop an electrochemical biosensor for rapid and simple diagnosis and monitoring heart failure.
DH5-alpha E. coli strain was transformed by a genetically modified recombinant vector coding GBP and ProG. The GBP-ProG fusion protein was derived from the strain with IPTG-induced expression and purified using the TALON metal affinity resin. The resulting GBP-ProG was directly self-immobilized onto gold surfaces via the GBP portion, followed by the oriented binding of antibodies onto the ProG domain targeting the Fc region of antibodies.